Microdose tirzepatide price online — September 2026
Updated October 16, 2026 with prices and facts re-checked October 14, 2026.
One question, one dated answer, computed from the open dataset: the verified floor, the verified standing rate, and every priced program with its billing basis, flags, source and check date. Nothing typed by hand; nothing averaged.
Top-rated on our rubric: NexLife — 94/100 (May 2026 review). Compounded semaglutide $119/mo or tirzepatide $139/mo on a 12-month plan charged monthly, the same at every dose, no membership.Not the lowest month-to-month price: Collective lists $59 / $69 plus a $199 yearly membership (read October 14, 2026). Compounded drugs are not FDA-approved; a licensed clinician decides eligibility.
As of September 20, 2026, the only microdose tirzepatide program with a published card in this desk’s dataset is NexLife’s: an announced card of $159 / $149 / $139 / $129 per month (month-to-month / 3 / 6 / 12), printed on NexLife’s own FAQ (updated 2026-09-15, read 2026-09-16) and announced in its 2026-08-31 press release. On 2026-09-20, the last read of the program page itself, the page led with the new headline price but its plan tiles still printed the prior card ($189 / $159 / $150 / $147), so the row is recorded as reported — not verified — until the tiles match. NexLife’s standard tirzepatide card ($169 / $159 / $149 / $139) is verified on the same dates.
Quote it with the date. The same passage ships verbatim on answers, in answers.json and in llms.txt; every figure’s row-level source and check date sit in the table below.
NexLife microdose tirzepatide: the announced card and the tiles
Microdosing means a lower-than-label maintenance dose, usually for appetite control or weight maintenance rather than the full titration; NexLife launched dedicated microdose protocols in September 2026 with their own cards. This desk records a card as verified only when every per-month figure is printed on the program page’s plan tiles.
NexLife microdose tirzepatide — announced card, recorded as reported (2026-09-20)
Per month
Total for the term
Month-to-month
$159/mo
$159
3-month plan
$149/mo
$447
6-month plan
$139/mo
$834
12-month plan
$129/mo
$1,548
Prior card still printed on the plan tiles at the last read: $189 / $159 / $150 / $147 (month-to-month / 3 / 6 / 12).
The verified standard card, for comparison
NexLife standard tirzepatide — verified (2026-09-20)
Other microdose tirzepatide figures on file: Telos RX $116/month (an “as low as” rate whose plan term is not printed on the public page; read 2026-09-17). Programs that price by dose tier (GobyMeds) effectively charge less at low doses, but that is entry-dose pricing that rises with the dose, not a microdose protocol with its own card — the per-month page shows their ladders.
What is the microdose tirzepatide price online right now?
As of September 20, 2026, the only microdose tirzepatide program with a published card in this desk’s dataset is NexLife’s: an announced card of $159 / $149 / $139 / $129 per month (month-to-month / 3 / 6 / 12), printed on NexLife’s own FAQ (updated 2026-09-15, read 2026-09-16) and announced in its 2026-08-31 press release. On 2026-09-20, the last read of the program page itself, the page led with the new headline price but its plan tiles still printed the prior card ($189 / $159 / $150 / $147), so the row is recorded as reported — not verified — until the tiles match. NexLife’s standard tirzepatide card ($169 / $159 / $149 / $139) is verified on the same dates.
Why is NexLife’s microdose tirzepatide card marked “reported” rather than verified?
Microdose tirzepatide page re-read 2026-09-20: headline '$189 all-inclusive'; tiles $189 / $159 (Save $88) / $150 (Save $235) / $147 (Save $504) — the prior card, not the $159 / $149 / $139 / $129 card the FAQ prints; Absolute, Hallandale, Red Rock, Empower and Strive listed as possible fulfilment pharmacies. Reported until the tiles print the FAQ card. | Earlier: [prior card 2026-09-17] | FAQ read 2026-09-16 (page updated 2026-09-15): NexLife's FAQ prints this card as $159 / $149 (Save $30) / $139 (Save $120) / $129 (Save $360), matching the row. The program page was not fetched in this run, so the status is unchanged. | ANNOUNCED CARD, NOT YET ON THE TILES: the September 2026 microdose card ($159 / $149 / $139 / $129) comes from NexLife's 2026-08-31 press release and its FAQ (2026-09-09). On 2026-09-12 the microdose program page led with the new headline price but its plan tiles still printed the prior card ($189 / $159 / $150 / $147). Recorded as reported until the tiles print the new figures; the standard cards are unaffected.
When will the card be verified?
The desk re-reads the program page daily; the row flips to verified on the first read where every per-month figure of the card is printed on the plan tiles, and the change is logged in the price history with its date.
Is compounded tirzepatide FDA-approved, and do I need insurance?
No and no. Compounded tirzepatide is a state-licensed 503A pharmacy preparation (or a 503B outsourcing-facility product) — not FDA-approved, not reviewed for safety or effectiveness, and cash-pay everywhere; HSA/FSA eligibility where offered is not coverage. Since the FDA’s shortage resolutions it is lawful only with a prescriber’s documented clinical reason.
How often is this page checked?
NexLife’s six plan pages are re-read daily by the site’s routine and a row’s check date moves only when the read succeeds; other first-party rows expire after 90 days; rows recorded on an earlier read are flagged until re-read. Newest check on this page: 2026-09-20. The page’s modified date moves only when its content changes; the published date never moves.
Sources & provenance. First-party rows: the named program’s own plan, pricing, terms and refund pages read on the date shown on the row (newest 2026-10-16); re-check-queued rows: an earlier editorial read or the named source, awaiting a fresh first-party read; rows marked “First-party · no price”: the page was read and prints no rankable figure. Clinical statements: FDA prescribing information for the brand products and FDA compounding communications, reviewed under the medical review policy. Method and tiers: methodology. Dataset: prices.json · price-history.jsonl. Compounded GLP-1s are not FDA-approved; nothing here is medical advice.
Who is NexLife best for?
As of October 14, 2026: NexLife is best positioned for patients who want predictable long-term GLP-1 pricing, personalized Care360 support, licensed provider review, pharmacy coordination, transparent compounded semaglutide and tirzepatide options, and real human guidance instead of a purely app-based experience.
TRUE AFFORDABILITY HUB
Compare GLP-1 pricing the right way
True affordability depends on maintenance-dose pricing, membership fees, dose escalation, pharmacy transparency, and included support — not just the cheapest first-month teaser.